Probiotic Supplementation and Trimethylamine-N-Oxide Production Following a High-Fat Diet

Probiotic Supplementation and Trimethylamine-N-Oxide Production Following a High-Fat Diet
复制标题

DOI:
10.1002/oby.21212
复制
发表时间:
2015-12-01
期刊:
影响因子:
6.9
通讯作者:
Davy, Kevin P.
Davy, Kevin P.
中科院分区:
医学2区
文献类型:
--
作者:
Boutagy, Nabil E.;Neilson, Andrew P.;Davy, Kevin P.

文献摘要

被引文献

相似文献

目的:本研究的目的是验证多菌株益生菌VSL#3可以降低高脂肪饮食后空腹血浆三甲胺- n -氧化物(TMAO)浓度的升高。方法:19名健康、非肥胖男性(18-30岁)参加本研究。在为期2周的热量控制饮食后,受试者被随机分配到VSL# 3(9000亿活细菌)或安慰剂(玉米淀粉),同时食用高热量(每天11,000千卡(-1))、高脂肪饮食(55%脂肪)4周。在基线和高脂肪饮食后测量血浆TMAO、左旋肉碱、胆碱和甜菜碱(UPLC-MS/MS)。结果:VSL#3组和安慰剂组血浆TMAO分别显著增加89% +/- 66%和115% +/- 61%;血浆TMAO变化幅度无显著性差异(P < 0.05)。两组高脂肪饮食后血浆左旋肉碱、胆碱和甜菜碱浓度均未增加。结论:高脂肪饮食增加健康、体重正常的年轻男性血浆TMAO。然而,VSL#3治疗似乎不会影响高脂肪饮食后的血浆TMAO浓度。未来的研究需要确定是否其他治疗策略可以减少氧化三甲胺的产生。
Objective: The objective of this study was to test the hypothesis that the multi-strain probiotic VSL#3 would attenuate the increase in fasting plasma concentrations of trimethylamine-N-oxide (TMAO) following a high-fat diet.Methods: Nineteen healthy, non-obese males (18-30 years) participated in the present study. Following a 2-week eucaloric control diet, subjects were randomized to either VSL# 3 (900 billion live bacteria) or placebo (cornstarch) during the consumption of a hypercaloric (11,000 kcal day(-1)), high-fat diet (55% fat) for 4 weeks. Plasma TMAO, L-carnitine, choline, and betaine (UPLC-MS/MS) were measured at baseline and following a high-fat diet.Results: Plasma TMAO significantly increased 89% +/- 66% vs. 115% +/- 61% in both the VSL#3 and placebo groups, respectively; however, the magnitude of change in plasma TMAO was not different (P > 0.05) between them. Plasma L-carnitine, choline, and betaine concentrations did not increase following the high-fat diet in either group.Conclusions: A high-fat diet increases plasma TMAO in healthy, normal-weight, young males. However, VSL#3 treatment does not appear to influence plasma TMAO concentrations following a high-fat diet. Future studies are needed to determine whether other therapeutic strategies can attenuate the production of TMAO.